journal article·2026-08Open access

Cantharidin-manganese based cocktail nanoplatform Co-activating ferroptosis and STING for enhanced HCC immunotherapy

Shengmei Wang, Mengtian Ma, Qiuyan Guo, Guiming Deng, Xinhua Xia, Jianyu Li, Xueqing Tao, Dong Zhong, Kun Zhang

Abstract

Hepatocellular carcinoma (HCC) is often identified during its advanced phases, where therapeutic choices are constrained and patient prognosis is generally poor, creating a critical need for innovative treatment approaches. Despite the promise of immunotherapy, its efficacy is frequently constrained by the immunosuppressive tumor microenvironment (TME). To address this, we developed a multifunctional nanoplatform (CTD/MM@BSA) via a facile "one-pot" method, co-delivering the chemotherapeutic agent cantharidin (CTD) and manganese ions (Mn2+) using bovine serum albumin (BSA). This platform leverages the synergistic interplay between ferroptosis induction and cGAS-STING pathway activation to remodel the TME. Upon internalization and subsequent release within tumor cells, CTD and Mn2+ act synergistically to boost intracellular ROS levels. This elevation promotes the induction of ferroptosis and ICD. The process culminates in the emission of DAMPs, which in turn activate the maturation of dendritic cells. Simultaneously, DNA damage triggered by CTD acts synergistically with the heightened sensitivity of cGAS to DNA in the presence of Mn2+, leading to a marked amplification of cGAS-STING pathway activation and the subsequent production of type I interferons. This bidirectional ferroptosis-immunity activation cascade effectively reverses immunosuppression, promoting cytotoxic T-cell responses. It markedly suppresses tumor growth and metastasis while extending the survival of mice. Moreover, when combined with an anti-PD-L1 antibody (aPD-L1), the therapy demonstrates a stronger synergistic anti-tumor effect. This study overcomes the limitations of free CTD (hepatorenal toxicity) and Mn2+ (poor tumor accumulation), offering a potent and targeted strategy to remodel the TME and boost anti-tumor immunity for HCC therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Cancer Mechanisms and Therapy · Beetle Biology and Toxicology Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Emerging immunotherapy or HCC: a guide for hepatologists10.1002/hep.32447 ↗
2. Recent advances of nanomedicines for liver cancer therapy10.1039/C9TB02871D ↗
3. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world10.3748/wjg.v23.i29.5282 ↗
4. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
5. IMMUNOTHERAPY Cancer immunotherapy and the value of cure10.1038/nrclinonc.2018.27 ↗
6. Genetically engineered T cell membrane-camouflaged nanoparticles triggered cuproptosis for synergistic bladder cancer photothermal-immunotherapy10.1186/s12951-025-03511-x ↗
7. Molecular mechanisms and cellular functions of cGAS-STING signalling10.1038/s41580-020-0244-x ↗
8. cGAS-STING, an important pathway in cancer immunotherapy10.1186/s13045-020-00916-z ↗
9. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy10.1186/s13045-019-0721-x ↗
10. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy10.1186/s12943-020-01250-1 ↗
11. Cuproptotic nanoinducer-driven proteotoxic stress potentiates cancer immunotherapy by activating the mtDNA-cGAS-STING signaling10.1016/j.biomaterials.2024.122512 ↗
12. Nanomedicine-mediated regulated cell death in cancer immunotherapy10.1016/j.jconrel.2023.10.032 ↗
13. Nanoscintillator-Mediated X-Ray-Triggered boosting transformation of Fe3+ into Fe2+ for enhancing tumor Ferroptosis/Immunotherapy10.1002/adfm.202301462 ↗
14. Multimodal synergistic ferroptosis cancer therapy10.1016/j.ccr.2024.216236 ↗
15. A "Closed-Loop" therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy10.1002/adfm.202111784 ↗
16. Spatiotemporal orchestration of a ferroptosis-immunotherapy "cycle" via a sequential drug delivery system for antitumor immunity10.1016/j.nantod.2024.102535 ↗
17. Specific activation of cGAS-STING pathway by nanotherapeutics- mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy10.1016/j.scib.2023.02.027 ↗
18. Ca & Mn dual-ion hybrid nanostimulator boosting anti-tumor immunity via ferroptosis and innate immunity awakening
19. A STING pathway-activatable contrast agent for MRI-guided tumor immunoferroptosis synergistic therapy
20. Liposomal delivery of MIW815 (ADU-S100) for potentiated STING activation10.3390/pharmaceutics15020638 ↗
21. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses10.1016/j.immuni.2018.03.017 ↗
22. ATP-Responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy10.1002/adma.202310189 ↗
23. Bimetallic plasmonic nanozyme-based microneedle for synergistic ferroptosis therapy of Melanoma10.1002/advs.202504203 ↗
24. Biodegradable long-circulating nanoagonists optimize tumor-tropism chemo-metalloimmunotherapy for boosted antitumor immunity by Cascade cGAS-STING pathway activation10.1021/acsnano.4c08463 ↗
25. Engineering Radiosensitizer-Based metal-phenolic networks potentiate STING pathway activation for advanced radiotherapy10.1002/adma.202105783 ↗
26. Overview of cantharidin and its analogues10.2174/0929867324666170414165253 ↗
27. Molecular modes of action of cantharidin in tumor cells10.1016/j.bcp.2004.12.003 ↗
28. Molecular biology of cantharidin in cancer cells10.1186/1749-8546-2-8 ↗
29. Cantharidin induces DNA damage and inhibits DNA repair-associated protein levels in NCI-H460 human lung cancer cells10.1002/tox.21986 ↗
30. Liposome encapsulation reduces cantharidin toxicity10.1016/j.fct.2008.06.084 ↗
31. Advances and prospects in integrated nano-oncology10.26599/NBE.2024.9290060 ↗
32. IR780/Gemcitabine-conjugated metal-phenolic network enhanced photodynamic cancer therapy10.1016/j.cclet.2023.108312 ↗
33. Non-cytotoxic nanoparticles re-educating macrophages achieving both innate and adaptive immune responses for tumor therapy
34. Manganese-based nanoadjuvants for the synergistic enhancement of immune responses in breast cancer therapy via disulfidptosis-induced ICD and cGAS-STING activation
35. Reduction sensitive polymers delivering cationic platinum drugs as STING agonists for enhanced chemo-immunotherapy10.1002/adfm.202204589 ↗
36. Activation of cGAS-STING signal to inhibit the proliferation of bladder cancer: the immune effect of Cisplatin10.3390/cells11193011 ↗
37. Manganese(ii) complexes stimulate antitumor immunity via aggravating DNA damage and activating the cGAS-STING pathway10.1039/D2SC06036A ↗
38. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and cancer immunotherapy10.1002/adma.202309562 ↗
39. Advances in the biological mechanism and application of manganese-based nanoformulations for enhanced immunotherapy10.1016/j.nantod.2022.101583 ↗
40. Samson · 2022
41. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy10.1038/s41422-020-00395-4 ↗
42. A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses10.1038/s41467-022-33301-0 ↗
43. cGAS-STING pathway in cancer biotherapy10.1186/s12943-020-01247-w ↗
44. Evoking and enhancing ferroptosis of cancer stem cells by a liver-targeted and metal-organic framework-based drug delivery system inhibits the growth and lung metastasis of hepatocellular carcinoma
45. Bio-inspired oxidative stress amplifier for suppressing cancer metastasis and imaging-guided combination therapy10.1021/acsami.2c22558 ↗
46. Nanomedicine-Based immunotherapy for the treatment of cancer metastasis10.1002/adma.201904156 ↗
47. Proteases in invasion: matrix metalloproteinases10.1006/scbi.2000.0365 ↗
48. Organizing 'Elements': facilitating exocytosis and promoting metastasis10.1016/j.trecan.2020.01.020 ↗